These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 29415929

  • 1. [Pharmacological, pharmaceutical and clinical profiles of sucroferric oxyhydroxide (P-TOL® Chewable Tab. 250 mg, 500 mg), a therapeutic agent for hyperphosphatemia].
    Tatemichi S, Nakagaki F, Yoshioka S, Shichiri N.
    Nihon Yakurigaku Zasshi; 2018; 151(2):75-86. PubMed ID: 29415929
    [Abstract] [Full Text] [Related]

  • 2. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Sucroferric Oxyhydroxide Study Group.
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [Abstract] [Full Text] [Related]

  • 3. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM, Floege J.
    Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
    [Abstract] [Full Text] [Related]

  • 4. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL, Plosker GL.
    Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
    Cozzolino M, Funk F, Rakov V, Phan O, Teitelbaum I.
    Curr Drug Metab; 2014 Apr; 15(10):953-65. PubMed ID: 25658128
    [Abstract] [Full Text] [Related]

  • 8. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A, Al-Makki A, Sutton J, Shepler B.
    Clin Ther; 2014 Dec 01; 36(12):2082-2093. PubMed ID: 25450474
    [Abstract] [Full Text] [Related]

  • 9. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
    Coyne DW, Sprague SM, Vervloet M, Ramos R, Kalantar-Zadeh K.
    J Nephrol; 2022 Apr 01; 35(3):875-888. PubMed ID: 35138627
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
    Suzuki D, Ichie T, Hayashi H, Sugiura Y, Sugiyama T.
    Pharmazie; 2017 Feb 01; 72(2):118-122. PubMed ID: 29441865
    [Abstract] [Full Text] [Related]

  • 12. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.
    Covic AC, Floege J, Ketteler M, Sprague SM, Lisk L, Rakov V, Rastogi A.
    Nephrol Dial Transplant; 2017 Aug 01; 32(8):1330-1338. PubMed ID: 27342579
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Iron-based phosphate binders--a new element in management of hyperphosphatemia.
    Pai AB, Jang SM, Wegrzyn N.
    Expert Opin Drug Metab Toxicol; 2016 Aug 01; 12(1):115-27. PubMed ID: 26572591
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.